Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients

Wacharee Seeherunvong, Obioma Nwobi, Carolyn L. Abitbol, Jayanthi Chandar, José Strauss, Gastón Zilleruelo

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Secondary hyperparathyroidism (SHPT) remains a treatment dilemma in pediatric dialysis patients. Recent experience with paricalcitol (P), a vitamin D analogue, in adults with SHPT has shown equal efficacy and improved survival compared to traditional treatment with calcitriol (C). We present our experience with (C) compared to (P) treatment in our pediatric dialysis patients with SHPT. Twenty-one patients (mean age 11.5±5 years) with SHPT (intact parathyroid hormone (iPTH) averaging 1,228±496 pg/ml) were studied. Seventeen received (C) followed by (P); while an additional four were treated with either (C=1) or (P=3) alone. After 26±8 weeks, average percent (%) decrease in iPTH was similar with (C) and (P) (-60.4±34% versus -65.4±28%, respectively; p=0.6). In the (P) group, the effective dose in children was greater than in adult trials based on kilogram weight. Episodes of hypercalcemia between the treatment groups were not different. However, episodes of elevated calcium × phosphorus product (Ca×P)≥70 mg2/dl2 occurred more frequently in the (C) group (odds ratio=1.5; p=0.01). Paricalcitol appears to be safe and effective in pediatric patients. Data suggest that dosing should be gauged according to degree of SHPT. This should serve as impetus for future pharmacokinetic studies in pediatric dialysis patients.

Original languageEnglish (US)
Pages (from-to)1434-1439
Number of pages6
JournalPediatric Nephrology
Volume21
Issue number10
DOIs
StatePublished - Oct 1 2006

Fingerprint

Secondary Hyperparathyroidism
Hyperparathyroidism
Calcitriol
Renal Dialysis
Pediatrics
Dialysis
Parathyroid Hormone
Therapeutics
Hypercalcemia
Vitamin D
Phosphorus
Pharmacokinetics
Odds Ratio
paricalcitol
Calcium
Weights and Measures
Survival

Keywords

  • Calcitriol
  • Children
  • Hemodialysis
  • Hyperparathyroidism
  • Paricalcitol
  • Young adults

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology

Cite this

Seeherunvong, W., Nwobi, O., Abitbol, C. L., Chandar, J., Strauss, J., & Zilleruelo, G. (2006). Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatric Nephrology, 21(10), 1434-1439. https://doi.org/10.1007/s00467-006-0204-5

Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. / Seeherunvong, Wacharee; Nwobi, Obioma; Abitbol, Carolyn L.; Chandar, Jayanthi; Strauss, José; Zilleruelo, Gastón.

In: Pediatric Nephrology, Vol. 21, No. 10, 01.10.2006, p. 1434-1439.

Research output: Contribution to journalArticle

Seeherunvong, W, Nwobi, O, Abitbol, CL, Chandar, J, Strauss, J & Zilleruelo, G 2006, 'Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients', Pediatric Nephrology, vol. 21, no. 10, pp. 1434-1439. https://doi.org/10.1007/s00467-006-0204-5
Seeherunvong, Wacharee ; Nwobi, Obioma ; Abitbol, Carolyn L. ; Chandar, Jayanthi ; Strauss, José ; Zilleruelo, Gastón. / Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. In: Pediatric Nephrology. 2006 ; Vol. 21, No. 10. pp. 1434-1439.
@article{a6f810f3c3434c33bdb13af56953621b,
title = "Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients",
abstract = "Secondary hyperparathyroidism (SHPT) remains a treatment dilemma in pediatric dialysis patients. Recent experience with paricalcitol (P), a vitamin D analogue, in adults with SHPT has shown equal efficacy and improved survival compared to traditional treatment with calcitriol (C). We present our experience with (C) compared to (P) treatment in our pediatric dialysis patients with SHPT. Twenty-one patients (mean age 11.5±5 years) with SHPT (intact parathyroid hormone (iPTH) averaging 1,228±496 pg/ml) were studied. Seventeen received (C) followed by (P); while an additional four were treated with either (C=1) or (P=3) alone. After 26±8 weeks, average percent ({\%}) decrease in iPTH was similar with (C) and (P) (-60.4±34{\%} versus -65.4±28{\%}, respectively; p=0.6). In the (P) group, the effective dose in children was greater than in adult trials based on kilogram weight. Episodes of hypercalcemia between the treatment groups were not different. However, episodes of elevated calcium × phosphorus product (Ca×P)≥70 mg2/dl2 occurred more frequently in the (C) group (odds ratio=1.5; p=0.01). Paricalcitol appears to be safe and effective in pediatric patients. Data suggest that dosing should be gauged according to degree of SHPT. This should serve as impetus for future pharmacokinetic studies in pediatric dialysis patients.",
keywords = "Calcitriol, Children, Hemodialysis, Hyperparathyroidism, Paricalcitol, Young adults",
author = "Wacharee Seeherunvong and Obioma Nwobi and Abitbol, {Carolyn L.} and Jayanthi Chandar and Jos{\'e} Strauss and Gast{\'o}n Zilleruelo",
year = "2006",
month = "10",
day = "1",
doi = "10.1007/s00467-006-0204-5",
language = "English (US)",
volume = "21",
pages = "1434--1439",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients

AU - Seeherunvong, Wacharee

AU - Nwobi, Obioma

AU - Abitbol, Carolyn L.

AU - Chandar, Jayanthi

AU - Strauss, José

AU - Zilleruelo, Gastón

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Secondary hyperparathyroidism (SHPT) remains a treatment dilemma in pediatric dialysis patients. Recent experience with paricalcitol (P), a vitamin D analogue, in adults with SHPT has shown equal efficacy and improved survival compared to traditional treatment with calcitriol (C). We present our experience with (C) compared to (P) treatment in our pediatric dialysis patients with SHPT. Twenty-one patients (mean age 11.5±5 years) with SHPT (intact parathyroid hormone (iPTH) averaging 1,228±496 pg/ml) were studied. Seventeen received (C) followed by (P); while an additional four were treated with either (C=1) or (P=3) alone. After 26±8 weeks, average percent (%) decrease in iPTH was similar with (C) and (P) (-60.4±34% versus -65.4±28%, respectively; p=0.6). In the (P) group, the effective dose in children was greater than in adult trials based on kilogram weight. Episodes of hypercalcemia between the treatment groups were not different. However, episodes of elevated calcium × phosphorus product (Ca×P)≥70 mg2/dl2 occurred more frequently in the (C) group (odds ratio=1.5; p=0.01). Paricalcitol appears to be safe and effective in pediatric patients. Data suggest that dosing should be gauged according to degree of SHPT. This should serve as impetus for future pharmacokinetic studies in pediatric dialysis patients.

AB - Secondary hyperparathyroidism (SHPT) remains a treatment dilemma in pediatric dialysis patients. Recent experience with paricalcitol (P), a vitamin D analogue, in adults with SHPT has shown equal efficacy and improved survival compared to traditional treatment with calcitriol (C). We present our experience with (C) compared to (P) treatment in our pediatric dialysis patients with SHPT. Twenty-one patients (mean age 11.5±5 years) with SHPT (intact parathyroid hormone (iPTH) averaging 1,228±496 pg/ml) were studied. Seventeen received (C) followed by (P); while an additional four were treated with either (C=1) or (P=3) alone. After 26±8 weeks, average percent (%) decrease in iPTH was similar with (C) and (P) (-60.4±34% versus -65.4±28%, respectively; p=0.6). In the (P) group, the effective dose in children was greater than in adult trials based on kilogram weight. Episodes of hypercalcemia between the treatment groups were not different. However, episodes of elevated calcium × phosphorus product (Ca×P)≥70 mg2/dl2 occurred more frequently in the (C) group (odds ratio=1.5; p=0.01). Paricalcitol appears to be safe and effective in pediatric patients. Data suggest that dosing should be gauged according to degree of SHPT. This should serve as impetus for future pharmacokinetic studies in pediatric dialysis patients.

KW - Calcitriol

KW - Children

KW - Hemodialysis

KW - Hyperparathyroidism

KW - Paricalcitol

KW - Young adults

UR - http://www.scopus.com/inward/record.url?scp=33747862682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747862682&partnerID=8YFLogxK

U2 - 10.1007/s00467-006-0204-5

DO - 10.1007/s00467-006-0204-5

M3 - Article

VL - 21

SP - 1434

EP - 1439

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 10

ER -